Edwards Lifesciences (EW) executive vests performance units and withholds shares for taxes
Rhea-AI Filing Summary
Edwards Lifesciences Corp executive Daveen Chopra reported routine equity compensation activity involving performance-based restricted stock units. Chopra exercised performance rights covering 13,583 shares of common stock, linked to awards granted on May 11, 2023 with three-year performance vesting.
In connection with vesting, 7,538 shares of common stock were disposed of to cover tax obligations at a price of $79.96 per share, rather than through an open-market sale. Following these transactions, Chopra holds 45,824 shares of Edwards Lifesciences common stock directly.
The board’s Compensation and Governance Committee previously determined that 167.70% of the target number of performance-based units would vest as of May 11, 2026, and this Form 4 reflects the resulting share delivery and tax-withholding disposition.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Performance Rights | 13,583 | $0.00 | $0.00 |
| Exercise | Common Stock | 13,583 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 7,538 | $79.96 | $603K |
Footnotes (2)
- F1. On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4.
- F2. These Performance Rights expire on May 10, 2030.
Key Figures
Key Terms
Performance Rights financial
restricted stock units financial
performance-based vesting requirements financial
tax-withholding disposition financial
derivative exercise/conversion financial
AI-generated analysis. How Rhea-AI works. Not financial advice.